Welcome to our dedicated page for Enhabit SEC filings (Ticker: EHAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enhabit, Inc. filings document formal disclosures for a public home health and hospice care provider. Recent reports include 8-K material-event disclosures, Regulation FD materials, operating and financial results, risk-factor updates, shareholder voting matters and capital-structure information.
The company’s SEC record also covers material definitive agreements, including credit facilities and related debt terms, governance matters such as officer transitions, and litigation-related disclosures involving claims connected to its home health and hospice business history. These filings frame Enhabit’s regulatory reporting around healthcare operations, financing arrangements, corporate governance and stockholder matters.
Enhabit, Inc. executive Jeanne Louise Kalvaitis, EVP of Hospice Operations, reported equity award activity and related tax withholding transactions in common stock. On February 27, 2026, she acquired 9,824 shares through a grant/award at $13.58 per share, tied to performance-based restricted stock units.
On February 27 and March 1, 2026, a total of 4,055 shares were disposed of at per‑share prices of $13.58 and $13.61 to satisfy tax withholding obligations on vested restricted stock, rather than through open‑market sales. After these transactions, she directly held 51,748 common shares.
Enhabit, Inc. reported that Senior Vice President and Chief Accounting Officer Collin McQuiddy has decided to resign, effective March 27, 2026. He will remain with the company until that date to help transition his responsibilities and is leaving to pursue another career opportunity.
The company stated there were no disagreements with Mr. McQuiddy regarding operations, policies, or practices. After the transition date, Chief Financial Officer Ryan Solomon will also serve as principal accounting officer until a successor is appointed, without any change or increase in his compensation.
Enhabit, Inc. agreed to be acquired by affiliates of Kinderhook Industries in an all‑cash merger at $13.80 per share. Each outstanding Enhabit common share (with limited exceptions) will be converted into the right to receive this cash amount at closing.
The deal implies a total enterprise value of about $1.1 billion and represents a 24.4% premium to Enhabit’s February 20, 2026 closing price and a 33.8% premium to its 60‑day volume‑weighted average price. After the merger, Enhabit will become a private company and its stock will be delisted from the New York Stock Exchange.
Equity awards will generally vest at the merger time and be cashed out at the $13.80 price, with out‑of‑the‑money options cancelled. Closing requires majority stockholder approval, antitrust and other regulatory clearances, and absence of a Company Material Adverse Effect, and is targeted for the second quarter of 2026.
8 Knots Management and affiliated funds report a significant passive stake in Enhabit, Inc. common stock. As of January 31, 2026, they beneficially own 5,057,352 shares, representing 9.99% of Enhabit’s 50,607,075 outstanding shares. The position is held through the 8 Knots Fund complex, a sub-advised fund, and several separately managed accounts, with varying levels of investment discretion and beneficial ownership. The filers certify the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of Enhabit.
Enhabit, Inc. filed a Form 8-K to share an update on a Delaware fiduciary duty case. Enhabit and Encompass Health Corporation have collected $43.1 million in full satisfaction of their claims for attorneys’ fees and mitigation damages from three individual defendants.
The companies will split the $43.1 million substantially equally. They also remain entitled, under a prior Court of Chancery order, to share 43% of VitalCaring Group’s ongoing profits and exit proceeds if and when VitalCaring is sold, through a constructive trust that is unchanged for the non-settling defendants.
Enhabit, Inc. director Barry P. Schochet reported receiving 2,382 shares of common stock on January 10, 2026. The shares were awarded at $9.97 per share and are structured as deferred stock units.
These units were taken in lieu of a cash retainer fee under the Enhabit, Inc. Deferred Director Compensation Plan. Following this transaction, Schochet beneficially owns 70,232 shares of Enhabit common stock in direct ownership.
Enhabit, Inc. director Stephan Rodgers reported receiving 1,881 shares of common stock on January 10, 2026 at a price of $9.97 per share. This was reported as an acquisition and increased his directly held position to 19,998 shares of Enhabit common stock.
According to the footnote, these 1,881 shares are deferred stock units granted in lieu of a cash retainer fee, based on his election under the Enhabit, Inc. Deferred Director Compensation Plan. This filing reflects routine director compensation paid in equity rather than cash.
Enhabit, Inc. director Mark W. Ohlendorf reported receiving 1,881 shares of common stock-equivalent deferred stock units on January 10, 2026. These units were taken instead of a cash retainer fee under the Enhabit, Inc. Deferred Director Compensation Plan, meaning the award represents routine board compensation rather than an open‑market purchase. The units were valued at a reference price of $9.97 per share.
After this grant, Ohlendorf beneficially owned 44,527 shares of Enhabit common stock in total, held directly. The filing confirms this was a single, non-derivative acquisition coded as an "A" transaction.
Enhabit, Inc. director Stuart M. McGuigan reported an acquisition of company equity as part of his board compensation. On January 10, 2026, he acquired 1,881 shares of Enhabit common stock at $9.97 per share, recorded as an "A" (acquired) transaction on a Form 4.
According to the footnote, these shares represent deferred stock units taken in lieu of a cash retainer fee under the Enhabit, Inc. Deferred Director Compensation Plan, reflecting an election to receive equity instead of cash. After this transaction, McGuigan beneficially owned 74,126 shares of Enhabit common stock, held directly.
Enhabit, Inc. director Charles M. Elson reported receiving 1,881 deferred stock units of common stock on January 10, 2026. These units were acquired at a reference price of $9.97 per share in lieu of a cash retainer fee, according to the company’s Deferred Director Compensation Plan.
After this grant, Elson beneficially owned 79,298 shares of Enhabit common stock in total, held directly. The transaction reflects routine director compensation being taken in equity rather than cash, aligning part of the director’s compensation with the company’s share performance.